Werewolf Therapeutics Inc
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies throu… Read more
Werewolf Therapeutics Inc (HOWL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.512x
Based on the latest financial reports, Werewolf Therapeutics Inc (HOWL) has a cash flow conversion efficiency ratio of -0.512x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.16 Million) by net assets ($29.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Werewolf Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Werewolf Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Werewolf Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Werewolf Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ene Technology Inc
TW:6243
|
0.020x |
|
CHINA DISPLAY O.T.H.HD-10
F:PJJ1
|
N/A |
|
Kbi Metal Co. Ltd
KQ:024840
|
0.043x |
|
Cypress Development Corp
OTCQX:CYDVF
|
-0.010x |
|
Ardea Resources Limited
PINK:ARRRF
|
-0.025x |
|
mySafety Group B
ST:SAFETY-B
|
-0.099x |
|
Kezar Life Sciences Inc
NASDAQ:KZR
|
-0.118x |
|
eXoZymes, Inc.
NASDAQ:EXOZ
|
-0.345x |
Annual Cash Flow Conversion Efficiency for Werewolf Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Werewolf Therapeutics Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $73.39 Million | $-56.19 Million | -0.766x | -161.46% |
| 2023-12-31 | $111.37 Million | $-32.61 Million | -0.293x | +11.76% |
| 2022-12-31 | $122.34 Million | $-40.60 Million | -0.332x | -18.25% |
| 2021-12-31 | $152.79 Million | $-42.88 Million | -0.281x | -34.43% |
| 2020-12-31 | $89.22 Million | $-18.62 Million | -0.209x | +78.63% |
| 2019-12-31 | $9.77 Million | $-9.54 Million | -0.977x | -- |